Mitochondrial Oxygen Tension Improves not upon Fluid Administration but after Transfusion of Erythrocytes (MOTIFATE) in chronic anemia patients (a pilot study)

Mitochondrial Oxygen Tension Improves not upon Fluid Administration but after Transfusion of Erythrocytes (MOTIFATE) in chronic anemia patients (a pilot study) - MOTIFATE-pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43442

Enrollment

Registered

2016-02-11

Start date

2016-03-21

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronicle anaemia low Hb level

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Be scheduled to receive a blood transfusion * Has a Hb level below the value indicated for red blood cell transfusion according to current transfusion guidelines for chronic anemia or * Has a Hb level above the value indicated for red blood cell transfusion according to current transfusion guidelines but presents with clinical symptoms of (too) low Hb (e.g. fatigue and general malaise).

Exclusion criteria

Exclusion criteria: * Age

Design outcomes

Primary

Measure	Time frame
The primary endpoint of the study is cellular oxygen availability in skin (mitoPO2 in mmHg) and its differential response to RBC transfusion compared to fluid challenge.	—

Secondary

Measure	Time frame
* Determine the cutaneous oxygen availability in relation to Hb level before and after a fluid challenge of 500 ml of normal saline. * Determine the cutaneous oxygen availability in relation to Hb level before and after a blood transfusion. * Determine the change in cutaneous oxygen availability by a fluid challenge of 500 ml of normal saline. * Determine the change in cutaneous oxygen availability by a blood transfusion. * Explore the clinical usability of the COMET monitor in blood transfusion treatments.	—

Measure

Time frame

* Determine the cutaneous oxygen availability in relation to Hb level before and after a fluid challenge of 500 ml of normal saline. * Determine the cutaneous oxygen availability in relation to Hb level before and after a blood transfusion. * Determine the change in cutaneous oxygen availability by a fluid challenge of 500 ml of normal saline. * Determine the change in cutaneous oxygen availability by a blood transfusion. * Explore the clinical usability of the COMET monitor in blood transfusion treatments.

—

Countries

Netherlands

Outcome results